Company / Revenue
Lexaria Bioscience Corp. Revenue History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$464.3K
FY2025
5-year range
$226.2K / $722.7K
FY2021-FY2025
Trend
+105.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue returned to growth in FY2025 after 2 years of decline, reaching $464,278.
Based on SEC 10-K filings.
$464,278 in FY2025 with a 5-year CAGR of +15.8%.
Improved from $255,397 to $464,278 over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- -13.7%
- 5-Year CAGR
- +15.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +15.8%, indicating consistent growth.
- In FY2025, revenue increased 105.2% year-over-year.
- Peak revenue was recorded in FY2022.
- Lowest revenue in the period was in FY2015.
Company context
Key Data Points
- Altman Z-Score -2.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $464.3K | +105.2% |
| FY2024 | $226.2K | -11.4% |
| FY2023 | $255.4K | -64.7% |
| FY2022 | $722.7K | +129.6% |
| FY2021 | $314.8K | +41.4% |
| FY2020 | $222.6K | -48.6% |
| FY2019 | $433.3K | +964.1% |
| FY2017 | $40.7K | +177.0% |
| FY2016 | $14.7K | - |
| FY2015 | $0 | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026